CYCC

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

Retrieved on: 
Monday, April 1, 2024
PD, Pharmacokinetics, ASCO, Annual general meeting, Patient, Cyclacel, CYCC, Society, Lymphoma, Safety, Pharmaceutical industry

BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as monotherapy was selected by the Scientific Program Committee for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.

Key Points: 
  • BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as monotherapy was selected by the Scientific Program Committee for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago.
  • Details of the presentations are as follows:
    A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 19, 2024
Research, Mutation, T-cell lymphoma, PD, ARID1A, Webcast, Patient, Lung, CDK, PLK1, Medicine, Clinical trial, CYCC, Cancer, Safety, Cyclacel, Lymphoma

BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.
  • These include pharmacokinetic (PK), pharmacodynamic (PD), safety and activity data from the dose escalation part of the 065-101 Phase 1/2 study.
  • "We expect to report final Phase 1 results including details on patient genomic profiles at an upcoming medical conference.
  • ( Webcast link )
    For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com .

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Webcast, Cyclacel, CYCC, Broadcasting

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.

Key Points: 
  • BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.
  • The Company will host a conference call at 4:30pm ET on the same day.
  • Webcast Link
    For the live and archived webcast, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com .
  • The webcast will be archived for 90 days and the audio replay for 7 days.

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, March 7, 2024
Lung cancer, Cyclacel, Cholangiocarcinoma, AACR, CYCC

BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that preclinical proof-of-concept data with the Company’s fadraciclib will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.

Key Points: 
  • BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that preclinical proof-of-concept data with the Company’s fadraciclib will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
  • The data will be presented at three poster sessions and report activity and antitumor effects of fadraciclib in biliary tract cancer, lung cancer, Richter transformation and lymphoma cell lines.
  • Details of the presentations are as follows:

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

Retrieved on: 
Wednesday, March 6, 2024
Cyclacel, HMRC, Medicine, CYCC

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government.

Key Points: 
  • BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it received £2.3 million (approximately $2.9 million) as a research & development (R&D) tax credit from HMRC, the tax agency of the United Kingdom government.
  • The tax credit is based on R&D costs incurred in the year ended December 31, 2023.
  • The Company expects to receive an additional approximately $0.8 million following confirmation of a change in the rate of tax credit regarding 2023 expenditures.
  • “The R&D tax credit has been an important source of non-dilutive capital supporting Cyclacel’s programs.

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Retrieved on: 
Tuesday, February 20, 2024
Cyclacel, BIO, Conference, CYCC

BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that Spiro Rombotis, President and Chief Executive Officer, is scheduled to present at the 2024 BIO CEO & Investor Conference taking place in-person at the New York Marriott Marquis on February 26-27, 2024.
  • The Company’s presentation is scheduled for Monday, February 26 at 2:30 PM ET in the Uris Room.
  • Mr. Rombotis will present an overview of Cyclacel’s business and programs.
  • The Company will be available for meetings with conference attendees which can be scheduled through the BIO One-on-One Partnering system: Here , or by emailing our corporate contacts using the information provided at the end of this press release.

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, January 30, 2024
Leo Pharma, Senior, CMO, Biomarker, Employment, Bayer, Drug development, CYCC, Medicine, Merck, Research and development, Hematology, University, Development, Merck & Co., Cyclacel, Pharmaceutical industry

will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately.

Key Points: 
  • will assume the role of interim Chief Medical Officer (“CMO”) of the Company effective immediately.
  • “We are delighted to have Brian join Cyclacel as CMO.
  • From June 2008 to 2020, he served as Senior Vice President, Head of Research & Development and Chief Medical Officer of ArQule Inc., which was acquired for $2.7bn by Merck & Co. in 2020.
  • Prior to ArQule, Dr. Schwartz was Chief Medical Officer at Ziopharm, having previously held several senior leadership roles at Bayer and LEO Pharma.

Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Retrieved on: 
Monday, January 8, 2024
Staff, CYCC, Cyclacel, Letter, Cryptocurrency

BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on January 4, 2024, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules.
  • As previously disclosed on July 7, 2023, the Company received a letter from the Listing Qualifications Staff (the “Staff”) of Nasdaq notifying the Company that Nasdaq had granted the Company a 180-day extension, or until January 2, 2024, to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share, to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2).
  • On January 4, 2024, the Company received a minimum bid price compliance letter from the Staff confirming the Company has regained compliance with Listing Rule 5550(a)(2), and that the matter is now closed.

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

Retrieved on: 
Tuesday, January 2, 2024
Cyclacel, CYCC

BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.

Key Points: 
  • BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Spiro Rombotis, President & Chief Executive Officer, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California.
  • Details of Cyclacel’s corporate update presentation are as follows:
    Location: Hilton San Francisco – Union Square, San Francisco, CA

Cyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq Rules

Retrieved on: 
Friday, December 22, 2023
Regulation D, Sale, Fifth Avenue, Ladenburg Thalmann, CYCC, Form, Cyclacel, Prospectus, 4th floor, Security (finance)

The closing of the offering is expected to occur on or about December 26, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about December 26, 2023, subject to the satisfaction of customary closing conditions.
  • Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $1.3 million.
  • A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.